Analyst: Positive results from Ambu's Duodeno 1.5 reflected in Ambu shares

On Monday, Ambu reported that 59 of 60 procedures completed with its improved duodenoscope, the Ascope Duodeno 1.5, were successful in a recent clinical test. An analyst from Sydbank sees the rewards in Ambu's share price.

Photo: Sydbank/PR

Today's positive results from Ambu's clinical study with its new and improved duodenoscope product, the Ascope Duodeno 1.5, have been received well by investors, who have sent Ambu's share price up, as observed by Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

On Monday morning, Ambu shares have increased in price by 5.4 percent to total DKK 200.1 (USD 30,4) on the stock exchange in Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs